Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia

Journal of Clinical Oncology

Volumn 32, Issue 9, 2014, Pages 949-959

  Bhojwani, Deepa ^a,b   Sabin, Noah D ^a   Pei, Deqing ^a   Yang, Jun J ^a,b   Khan, Raja B ^a   Panetta, John C ^a   Krull, Kevin R ^a   Inaba, Hiroto ^a,b   Rubnitz, Jeffrey E ^a,b   Metzger, Monika L ^a,b   Howard, Scott C ^a,b   Ribeiro, Raul C ^a,b   Cheng, Cheng ^a   Reddick, Wilburn E ^a   Jeha, Sima ^a,b   Sandlund, John T ^a,b   Evans, William E ^a   Pui, Ching Hon ^a,b   Relling, Mary V ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; FOLIC ACID; FOLINIC ACID; HYDROCORTISONE; METHOTREXATE; VINCRISTINE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; ATAXIA; CANCER CHEMOTHERAPY; CANCER PATIENT; CEREBROVASCULAR ACCIDENT; CHILD; CHILDHOOD LEUKEMIA; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG MEGADOSE; DRUG SAFETY; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; HUMAN; LEUKOENCEPHALOPATHY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUROIMAGING; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHARMACOGENETICS; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENT DISEASE; SCHOOL CHILD; SEIZURE; YOUNG ADULT; BRAIN; CHEMICALLY INDUCED DISORDER; GENETIC PREDISPOSITION; GENETICS; MUTATION; PATHOLOGY; RISK FACTOR; STATISTICAL MODEL; TOXICITY AND INTOXICATION;

ADOLESCENT; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN; CHILD; CHILD, PRESCHOOL; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; GERM-LINE MUTATION; HUMANS; LEUCOVORIN; LEUKOENCEPHALOPATHIES; LOGISTIC MODELS; MAGNETIC RESONANCE IMAGING; MALE; METHOTREXATE; NEUROTOXICITY SYNDROMES; POLYMORPHISM, GENETIC; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84899638189     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.53.0808     Document Type: Article

References (47)

1. Inaba H, Khan RB, Laningham FH, et al: Clinical and radiological characteristics of methotrexate-induced acute encephalopathy in pediatric patients with cancer. Ann Oncol 19:178-184, 2008
2. Rubnitz JE, Relling MV, Harrison PL, et al: Transient encephalopathy following high-dose methotrexate treatment in childhood acute lymphoblastic leukemia. Leukemia 12:1176-1181, 1998 (Pubitemid 28395978)
3. Winick NJ, Bowman WP, Kamen BA, et al: Unexpected acute neurologic toxicity in the treatment of children with acute lymphoblastic leukemia. J Natl Cancer Inst 84:252-256, 1992
4. Dufourg MN, Landman-Parker J, Auclerc MF, et al: Age and high-dose methotrexate are associated to clinical acute encephalopathy in FRALLE 93 trial for acute lymphoblastic leukemia in children. Leukemia 21:238-247, 2007 (Pubitemid 46158115)
5. Mahoney DH Jr, Shuster JJ, Nitschke R, et al: Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: An association with intermediate-dose intravenous methotrexate and intrathecal triple therapy - A Pediatric Oncology Group study. J Clin Oncol 16:1712-1722, 1998
6. Buizer AI, de Sonneville LM, van den Heuvel-Eibrink MM, et al: Behavioral and educational limitations after chemotherapy for childhood acute lymphoblastic leukemia or Wilms tumor. Cancer 106:2067-2075, 2006 (Pubitemid 43673224)
7. Cole PD, Beckwith KA, Vijayanathan V, et al: Folate homeostasis in cerebrospinal fluid during therapy for acute lymphoblastic leukemia. Pediatr Neurol 40:34-41, 2009
8. Vezmar S, Schüsseler P, Becker A, et al: Methotrexate-associated alterations of the folate and methyl-transfer pathway in the CSF of ALL patients with and without symptoms of neurotoxicity. Pediatr Blood Cancer 52:26-32, 2009
9. Vezmar S, Becker A, Bode U, et al: Biochemical and clinical aspects of methotrexate neurotoxicity. Chemotherapy 49:92-104, 2003 (Pubitemid 36469805)
10. Kishi S, Griener J, Cheng C, et al: Homocysteine, pharmacogenetics, and neurotoxicity in children with leukemia. J Clin Oncol 21:3084-3091, 2003 (Pubitemid 46606289)
11. Rollins N, Winick N, Bash R, et al: Acute methotrexate neurotoxicity: Findings on diffusion-weighted imaging and correlation with clinical outcome. AJNR Am J Neuroradiol 25:1688-1695, 2004 (Pubitemid 44123692)
12. Asato R, Akiyama Y, Ito M, et al: Nuclear magnetic resonance abnormalities of the cerebral white matter in children with acute lymphoblastic leukemia and malignant lymphoma during and after central nervous system prophylactic treatment with intrathecal methotrexate. Cancer 70:1997-2004, 1992
13. Oka M, Terae S, Kobayashi R, et al: MRI in methotrexate-related leukoencephalopathy: Disseminated necrotising leukoencephalopathy in comparison with mild leukoencephalopathy. Neuroradiology 45:493-497, 2003 (Pubitemid 36944066)
14. Robain O, Dulac O, Dommergues JP, et al: Necrotising leukoencephalopathy complicating treatment of childhood leukaemia. J Neurol Neurosurg Psychiatry 47:65-72, 1984 (Pubitemid 14154241)
15. Reddick WE, Glass JO, Helton KJ, et al: Prevalence of leukoencephalopathy in children treated for acute lymphoblastic leukemia with high-dose methotrexate. AJNR Am J Neuroradiol 26:1263-1269, 2005 (Pubitemid 43821984)
16. Reddick WE, Conklin HM: Impact of acute lymphoblastic leukemia therapy on attention and working memory in children. Expert Rev Hematol 3:655-659, 2010
17. Kishi S, Cheng C, French D, et al: Ancestry and pharmacogenetics of antileukemic drug toxicity. Blood 109:4151-4157, 2007 (Pubitemid 46743376)
18. Vagace JM, Caceres-Marzal C, Jimenez M, et al: Methotrexate-induced subacute neurotoxicity in a child with acute lymphoblastic leukemia carrying genetic polymorphisms related to folate homeostasis. Am J Hematol 86:98-101, 2011
19. Pui CH, Campana D, Pei D, et al: Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med 360:2730-2741, 2009
20. Mikkelsen TS, Sparreboom A, Cheng C, et al: Shortening infusion time for high-dose methotrexate alters antileukemic effects: A randomized prospective clinical trial. J Clin Oncol 29:1771-1778, 2011
21. Pauley JL, Panetta JC, Crews KR, et al: Between-course targeting of methotrexate exposure using pharmacokinetically guided dosage adjustments. Cancer Chemother Pharmacol 72: 369-378, 2013
22. Ruhs H, Becker A, Drescher A, et al: Population PK/PD model of homocysteine concentrations after high-dose methotrexate treatment in patients with acute lymphoblastic leukemia. PLoS One 7:e46015, 2012
23. Trevino LR, Shimasaki N, Yang W, et al: Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol 27:5972-5978, 2009
24. Breiman L, Friedman JH, Olshen RA, et al: Classification and Regression Trees. Belmont, CA, Wadsworth International Group, 1984
25. Kawedia JD, Kaste SC, Pei D, et al: Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia. Blood 117:2340-2347, 2011
26. Pritchard JK, Stephens M, Donnelly P: Inference of population structure using multilocus genotype data. Genetics 155:945-959, 2000 (Pubitemid 30397141)
27. Reimand J, Arak T, Vilo J: G:Profiler: A Web server for functional interpretation of gene lists (2011 update). Nucleic Acids Res 39:W307-W315, 2011
28. Bernini JC, Fort DW, Griener JC, et al: Aminophylline for methotrexate-induced neurotoxicity. Lancet 345:544-547, 1995
29. Chu WC, Chik KW, Chan YL, et al: White matter and cerebral metabolite changes in children undergoing treatment for acute lymphoblastic leukemia: Longitudinal study with MR imaging and 1H MR spectroscopy. Radiology 229:659-669, 2003 (Pubitemid 37467566)
30. Pääkkö E, Harila-Saari A, Vanionpää L, et al: White matter changes on MRI during treatment in children with acute lymphoblastic leukemia: Correlation with neuropsychological findings. Med Pediatr Oncol 35:456-461, 2000
31. Reddick WE, Glass JO, Helton KJ, et al: A quantitative MR imaging assessment of leukoencephalopathy in children treated for acute lymphoblastic leukemia without irradiation. AJNR Am J Neuroradiol 26:2371-2377, 2005
32. Möricke A, Reiter A, Zimmermann M, et al: Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: Treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood 111:4477-4489, 2008
33. Bateman J, Van Vactor D: The Trio family of guanine-nucleotide-exchange factors: Regulators of axon guidance. J Cell Sci 114:1973-1980, 2001 (Pubitemid 32586623)
34. Zhao Z, Wang Z, Gu Y, et al: Regulate axon branching by the cyclic GMP pathway via inhibition of glycogen synthase kinase 3 in dorsal root ganglion sensory neurons. J Neurosci 29:1350-1360, 2009
35. Hakanen J, Duprat S, Salminen M: Netrin1 is required for neural and glial precursor migrations into the olfactory bulb. Dev Biol 355:101-114, 2011
36. Wilson PM, Fryer RH, Fang Y, et al: Astn2, a novel member of the astrotactin gene family, regulates the trafficking of ASTN1 during glial-guided neuronal migration. J Neurosci 30:8529-8540, 2010
37. Susuki K, Rasband MN: Spectrin and ankyrin-based cytoskeletons at polarized domains in myelinated axons. Exp Biol Med (Maywood) 233:394-400, 2008 (Pubitemid 351469294)
38. Zhou D, Wang J, Zapala MA, et al: Gene expression in mouse brain following chronic hypoxia: Role of sarcospan in glial cell death. Physiol Genomics 32:370-379, 2008 (Pubitemid 351328560)
39. Diep DB, Hoen N, Backman M, et al: Characterisation of the Wnt antagonists and their response to conditionally activated Wnt signalling in the developing mouse forebrain. Brain Res Dev Brain Res 153:261-270, 2004 (Pubitemid 39441042)
40. Lee JW, Yeo SG, Kang BH, et al: Echovirus 30 induced neuronal cell death through TRIO-RhoA signaling activation. PLoS One 7:e36656, 2012
41. Glessner JT, Wang K, Cai G, et al: Autism genome-wide copy number variation reveals ubiquitin and neuronal genes. Nature 459:569-573, 2009
42. Freilinger T, Anttila V, de Vries B, et al: Genome-wide association analysis identifies susceptibility loci for migraine without aura. Nat Genet 44:777-782, 2012
43. Lionel AC, Crosbie J, Barbosa N, et al: Rare copy number variation discovery and cross-disorder comparisons identify risk genes for ADHD. Sci Transl Med 3:95ra75, 2011
44. Neale BM, Medland S, Ripke S, et al: Case-control genome-wide association study of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 49:906-920, 2010
45. Fallin MD, Szymanski M, Wang R, et al: Fine mapping of the chromosome 10q11-q21 linkage region in Alzheimer's disease cases and controls. Neurogenetics 11:335-348, 2010
46. Conklin HM, Krull KR, Reddick WE, et al: Cognitive outcomes following contemporary treatment without cranial irradiation for childhood acute lymphoblastic leukemia. J Natl Cancer Inst 104:1386-1395, 2012
47. Krull KR, Bhojwani D, Conklin HM, et al: Genetic mediators of neurocognitive outcomes in survivors of childhood acute lymphoblastic leukemia. J Clin Oncol 31:2182-2188, 2013